Developing a new method to enhance T-cell responses to cancer vaccines
Rational in situ programming of cancer vaccine-responding T-cell clones
This study is looking at a new way to make cancer vaccines work better by using tiny injections that help your immune cells recognize and fight cancer more effectively, which could lead to improved results for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10873982 on NIH RePORTER |
What this research studies
This research aims to improve the effectiveness of cancer vaccines by using injectable nanoreagents that introduce engineered T-cell receptors (TCRs) into the body's T-cell population. By programming these TCRs to specifically recognize tumor antigens, the study seeks to enhance the immune response against cancer cells. The approach combines advanced bioengineering techniques with immunology to create a more robust and targeted immune response, potentially leading to better outcomes for patients receiving cancer vaccines.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancer who are eligible for immunotherapy and have not responded adequately to existing vaccine treatments.
Not a fit: Patients who do not have cancer or those whose tumors are not amenable to immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer vaccines that significantly improve patient outcomes by enhancing the immune system's ability to fight tumors.
How similar studies have performed: Previous research has shown promise in using engineered TCRs and nanoparticles for enhancing immune responses, indicating that this approach may lead to significant advancements in cancer treatment.
Where this research is happening
Seattle, United States
- Fred Hutchinson Cancer Center — Seattle, United States (Active)
Researchers
- Principal investigator: Stephan, Matthias — Fred Hutchinson Cancer Center
- Study coordinator: Stephan, Matthias
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.